Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104

AC Immune AG (ACIU.O):

• AC Immune reports positive safety & immunogenicity at week-100 in Part 1 of Vacsyn Phase 2 trial of ACI-7104
• AC Immune AG - all primary endpoints met in Part 1 of Vacsyn Phase 2 trial for ACI-7104
• AC Immune AG - discussions with FDA regarding ACI-7104 development path planned for early 2027

Source text: ID:nGNX52qtkv

Further company coverage: ACIU.O